2019
Clinical characteristics and outcomes of patients with Escherichia coli in airway samples
Schneer S, Khoury J, Adir Y, Stein N, Mishan P, Ken‐Dror S, Weber G, Meler R, Khateeb A, Shteinberg M. Clinical characteristics and outcomes of patients with Escherichia coli in airway samples. The Clinical Respiratory Journal 2019, 14: 205-213. PMID: 31799802, DOI: 10.1111/crj.13116.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Bacterial AgentsBronchiectasisCase-Control StudiesCommunity-Acquired InfectionsCross InfectionCystic FibrosisDrug Resistance, BacterialEscherichia coliEscherichia coli InfectionsFemaleHospitalizationHumansMaleMicrobial Sensitivity TestsMiddle AgedRespiratory Tract InfectionsSputumConceptsRespiratory secretionsResistant E. coliE. coli positive culturesResistant strainsMore hospitalization daysOutcomes of patientsGroup of patientsCommunity-acquired infectionsClinical characteristicsHospital daysPulmonary infectionHospitalization daysAmbulatory patientsPrevious hospitalizationAirway samplesPrognostic valueRespiratory pathogensCommon pathogensPositive culturesPatientsNosocomial pathogenAntibiotic classesAntimicrobial classesSecretionElevated mortalityThe association between fluconazole dose and MIC with mortality and persistence in candidemia
Ghanem-Zoubi N, Qasum M, Khoury J, Zorbavel D, Arnon M, Geffen Y, Paul M. The association between fluconazole dose and MIC with mortality and persistence in candidemia. European Journal Of Clinical Microbiology & Infectious Diseases 2019, 38: 1773-1780. PMID: 31197619, DOI: 10.1007/s10096-019-03611-1.Peer-Reviewed Original ResearchConceptsAUC24/MICClinical outcomesC. glabrata candidemiaComposite of mortalityExposure parametersLowest MIC valueSimilar non-significant differencesFluconazole doseFluconazole dosingPersistent candidemiaSingle centerMIC valuesClinical failureInclusion criteriaCandidemiaPatientsDay 14Non-significant differenceHigh MICsFluconazole MICsStudy periodMortalityCandida speciesMICC. glabrata
2018
The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study
Ghanem-Zoubi N, Zorbavel D, Khoury J, Geffen Y, Qasum M, Predescu S, Paul M. The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study. European Journal Of Clinical Microbiology & Infectious Diseases 2018, 37: 2397-2404. PMID: 30284179, DOI: 10.1007/s10096-018-3389-1.Peer-Reviewed Original ResearchConceptsCLSI 2012Appropriate antifungal treatmentDefinitive treatmentOdds ratioAntifungal treatmentAntimicrobial Susceptibility Testing (EUCAST) breakpointsAppropriate definitive treatmentRetrospective observational studyAdjusted odds ratioAppropriate empirical treatmentBivariate logistic regressionCandidemia onsetCandidemia episodesEmpiric treatmentTreatment appropriatenessTertiary centerRetrospective studyCLSI breakpointsEmpirical treatmentObservational studyBreakpoint definitionPatientsResistance prevalenceMortalityLogistic regression
2017
Secondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults
Khoury J, Geffen Y, Shaul R, Sholy H, Chowers Y, Saadi T. Secondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults. Journal Of Global Antimicrobial Resistance 2017, 10: 182-185. PMID: 28732784, DOI: 10.1016/j.jgar.2017.05.017.Peer-Reviewed Original ResearchConceptsH. pylori culturePositive H. pylori culturePylori cultureTherapeutic regimensH. pyloriRambam Health Care CampusSecondary antibiotic resistanceHelicobacter pylori infectionHealth Care CampusAntibiotic resistanceH. pylori strainsHelicobacter pylori isolatesStandard therapyPylori infectionGastric biopsiesSecondary antimicrobial resistanceLEV resistancePylori isolatesPatientsAntimicrobial susceptibilityClarithromycinPylori strainsMetronidazoleAmoxicillinAntimicrobial resistance